MCRB vs. RGLS, RNAC, RAPT, CYBN, SGMT, PDSB, KPTI, CNTX, OPTN, and AMLX
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Regulus Therapeutics (RGLS), Cartesian Therapeutics (RNAC), RAPT Therapeutics (RAPT), Cybin (CYBN), Sagimet Biosciences (SGMT), PDS Biotechnology (PDSB), Karyopharm Therapeutics (KPTI), Context Therapeutics (CNTX), OptiNose (OPTN), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical preparations" industry.
Regulus Therapeutics (NASDAQ:RGLS) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment.
Regulus Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 262.50%. Seres Therapeutics has a consensus price target of $5.00, indicating a potential upside of 443.54%. Given Regulus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Regulus Therapeutics.
In the previous week, Seres Therapeutics had 2 more articles in the media than Regulus Therapeutics. MarketBeat recorded 5 mentions for Seres Therapeutics and 3 mentions for Regulus Therapeutics. Seres Therapeutics' average media sentiment score of 0.61 beat Regulus Therapeutics' score of -0.24 indicating that Regulus Therapeutics is being referred to more favorably in the media.
92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Regulus Therapeutics' return on equity of 0.00% beat Seres Therapeutics' return on equity.
Seres Therapeutics received 43 more outperform votes than Regulus Therapeutics when rated by MarketBeat users. Likewise, 72.48% of users gave Seres Therapeutics an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
Regulus Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.
Regulus Therapeutics has higher earnings, but lower revenue than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Seres Therapeutics beats Regulus Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
